Irlanda - anglès - HPRA (Health Products Regulatory Authority)

recordati industria chimica e farmaceutica spa - leuprorelin acetate - powder and solvent for solution for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

recordati industria chimica e farmaceutica spa - leuprorelin acetate - powder and solvent for solution for injection - 45 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

recordati industria chimica e farmaceutica spa - leuprorelin acetate - powder and solvent for solution for injection - 7.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Estats Units - anglès - NLM (National Library of Medicine)

amway corp - octinoxate 7.5%, zinc oxide 6.528%, octisalate 5.0%, titanium dioxide 2.49% - shake bottle well. after applying moisturizer, smooth a liberal amount over face and neck with your fingertips. use every morning. helps prevent sunburn

Estats Units - anglès - NLM (National Library of Medicine)

liddell laboratories, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl), sus scrofa pituitary gland (unii: l0pfemq1dt) (sus scrofa pituitary gland - unii:l0pfemq1dt), pork liver (unii: 6ec706hi7f) (pork liver - unii:6ec706hi7f) - may temporarily relieve these symptoms due to aging and/or a run-down condition:  - low energy - lack of vigor - occasional sleeplessness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve these symptoms due to aging and/or a run-down condition: low energy lack of vigor occasional sleeplessness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

concept laboratories pty ltd - butyl methoxydibenzoylmethane, quantity: 40 mg/g; 4-methylbenzylidene camphor, quantity: 40 mg/g; octocrylene, quantity: 40 mg/g; ethylhexyl triazone, quantity: 30 mg/g - lotion - excipient ingredients: caprylyl glycol; purified water; glycerol; citric acid; octanohydroxamic acid; colloidal anhydrous silica; white beeswax; peg-40 stearate; dl-alpha-tocopheryl acetate; peg-15 cocamine; alkyl (c12-15) benzoate; aloe vera; ammonium acryloyldimethyltaurate/vp copolymer; dexpanthenol; hyetellose - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

concept laboratories pty ltd - 4-methylbenzylidene camphor,butyl methoxydibenzoylmethane,ethylhexyl triazone,octocrylene -

Estats Units - anglès - NLM (National Library of Medicine)

energique, inc. - 7-oxodehydroepiandrosterone 3-acetate (unii: 84rq0xom11) (7-oxodehydroepiandrosterone 3-acetate - unii:84rq0xom11), oyster shell calcium carbonate, crude (unii: 2e32821g6i) (oyster shell calcium carbonate, crude - unii:2e32821g6i), conium maculatum flowering top (unii: q28r5gf371) (conium maculatum flowering top - unii:q28r5gf371), sus scrofa adrenal gland (unii: 398iyq16yv) (sus scrofa adrenal gland - unii:398iyq16yv), pork liver (unii: 6ec706hi7f) (pork liver - unii:6ec706hi7f), hydrofluoric acid (un - may temporarily relieve symptoms associated with premature aging, such as fatigue, loss of strength, aging skin, varicose veins, sleeplessness and, forgetfulness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms associated with premature aging, such as fatigue, loss of strength, aging skin, varicose veins, sleeplessness and, forgetfulness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Israel - anglès - Ministry of Health

bayer israel ltd - interferon beta 1b - powder and solvent for solution for injection - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - interferon beta-1a, quantity: 60 microgram/ml - injection, solution - excipient ingredients: arginine hydrochloride; polysorbate 20; sodium acetate; water for injections; glacial acetic acid - avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis (ms). avonex is indicated in patients who have experienced a single demyelinating event and are at risk of developing clinically definite ms based on the presence of brain mri abnormalities characteristic of ms. avonex 60 mcg is indicated for the treatment of secondary progressive ms in patients in whom relapse is still a feature of disease. avonex 60 mcg should not be initiated in patients with secondary progressive ms who have not experienced relapse in the previous 12 months.